Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 9, 2010

Eisai Gains U.S. Commercialization Rights to Helsinn’s Combination Antiemetic

  • Eisai negotiated U.S. co-promotion rights to Helsinn Healthcare’s Phase III drug candidate for the prevention of chemotherapy-induced nausea and vomiting. The drug is an oral- and IV-formulated, fixed-dose combination of the neurokinin-1 receptor antagonist, netupitant, and the serotonin-3 (5-HT3) receptor antagonist, palonosetron.

    Helsinn will be responsible for carrying out all development and regulatory activities. If approved by FDA, the new products will be co-promoted in the U.S. by Eisai. Helsinn’s manufacturing affiliate in Ireland, Helsinn Birex Pharmaceuticals, will manufacture and supply the finished product for clinical and commercial use in the U.S.

    Eisai and Helsinn also signed a detail service agreement to co-promote the existing palonosetron drug, Aloxi®, in the U.S. Helsinn says that it will recruit and hire a dedicated sales force.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »